Access to TB Drugs and Diagnostics Gregg Gonsalves Open Society Foundations Division of the Epidemiology of Microbial Diseases, Yale School of Public Health.

Slides:



Advertisements
Similar presentations
The TB Alliance-Bayer Moxifloxacin Deal
Advertisements

Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.
Multidrug- resistant tuberculosis: update Multidrug-resistant TB in the world update October 2012  WHO 2012 © World Health Organization 2012.
TB and HIV: Tightly Linked… and Why We Should Care.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
Multi-drug Resistant Tuberculosis Hail M. Al-Abdely Consultant, Infectious Diseases, KFSH&RC.
World Tuberculosis Day 2015 The TB situation in 2013: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
World Tuberculosis Day 2014 The TB situation in 2012: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
MDR and XDR TB Bruce A. Bush, M.D. Regional Tuberculosis Consultant
What, Where, How and Action Steps… XDR-TB
The Global Plan to Stop TB, (1)
1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.
Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.
Module 1: Overview of tuberculosis (TB) and TB diagnostics Global Laboratory Initiative – Xpert MTB/RIF Training Package.
The global TB situation (1)
Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director
MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.
PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,
Global and U.S. Tuberculosis Epidemiology and Principles of Control
EMERGING INFECTIOUS DISEASES: A CONTINUOUS CHALLENGE FOR EUROPE STOA-AVIESAN WORKSHOP JUNE 19TH 2012; EUROPEAN PARLIAMENT; BRUXELLES A sustainable agenda.
Overview of this presentation Burden of TB, TB/HIV, MDR-TB Progress towards international targets Challenges in 2011 Actions needed.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps…
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
14 th Meeting of the Core Group of the TB/HIV Working Group Addis Ababa, Ethiopia November 12, 2008 MDR and XDR-TB in the context of HIV: What next? Paul.
DOTS Expansion: Monitoring Drugs Leopold Blanc TBS, Stop TB WHO, Communicable Diseases.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.
International Health Policy Program -Thailand Policy decision on multi drug resistant(MDR), extreme drug resistant(XDR) tuberculosis screening: How it.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Abstract Modern chemotherapy has played a major role in our control of tuberculosis. Yet tuberculosis still remains a leading infectious disease worldwide.
TB Control Measures: From development and endorsement to adoption and implementation Léopold Blanc TBS Stop TB department WHO Christy Garcia University.
Strategic Information and the Control of Tuberculosis Brian Williams and Chris Dye TB programme, Monitoring and Evaluation, WHO.
Moving ahead with the Stop TB Strategy: where are we today? Dr Mario Raviglione Director, WHO Stop TB Department Joint Meeting of Core Teams and High Burden.
Current Health Concerns: Tuberculosis Saharwash Jamali Hamna Jaffar.
Dr Ral Antic Chair Scientific Committee IUATLD-APR Australia Pre-Conference Workshop 1 National TB Control Program Summary & Remarks.
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.
Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis UZ-UCSF ARD April 08, 2016 W.Samaneka MBChB, MSc Clin Epi, Dip HIV Man.
Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N Engl J Med 2008;359: R2 이 설 라.
The story of Munya* (and us)
Palliative Care and M/XDR-TB Global burden of M/XDR-TB
financial requirements
World Tuberculosis Day 2013
World Tuberculosis Day 2014
reporting rate of discarded cases* per 100'000 population**
اپيدميولوژي و كنترل سِل
Multidrug-/ rifampicin-resistant TB
PROGRESS IN GLOBAL TB CONTROL
World Tuberculosis Day 2015
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
Tuberculosis situation in the EU/EEA, 2016
World Tuberculosis Day 2014
Countries Having Introduced Hib Vaccine
Non-polio AFP Rate July 2014 – June 2015 July 2015 – June 2016
(70 countries or 36%) (23 countries or 12%)
Countries with Genotype data available
Countries having introduced HepB vaccine
Countries Using Mening Vaccine in National Immunization Schedule 2011
Onset of most recent case Number of infected districts
PROGRESS IN GLOBAL TB CONTROL
THE GLOBAL EPIDEMIOLOGY OF TUBERCULOSIS WORLD HEALTH ORGANIZATION
Meningitis/Encephalitis Surveillance Countries reporting to WHO Network or with Other (non-WHO Network) Surveillance Activities WHO Network (46 member.
2,100 4,200 1,050 Kilometers < 90% (75 countries or 39%)
Presentation transcript:

Access to TB Drugs and Diagnostics Gregg Gonsalves Open Society Foundations Division of the Epidemiology of Microbial Diseases, Yale School of Public Health Department of Global Health and Social Medicine, Harvard Medical School

The global TB situation Estimated number of cases, 2010 Estimated number of deaths, million* (0.9–1.2 million) 8.8 million (8.5–9.2 million) ~ 650,000 out of 12 million (11-14 million) prevalent TB cases All forms of TB Multidrug- resistant TB HIV-associated TB 1.1 million (1.0–1.2 million) 350,000 (320,000–390,000) Source: WHO Global Tuberculosis Control Report 2011 ( ) * Excluding deaths attributed to HIV/TB

0–24 25–49 50–99 100–299 >300 No estimate Highest burden in Asia (55% of 9.4 million cases) Highest rates in Africa, due to high HIV infection rate ~80% of HIV+ TB cases in Africa Per population TB Incidence Rates Africa 30% West Pacific 20% SE Asia 35% Europe 4% East Mediterranean 7% Americas 3%

Impact of HIV on TB in Africa Notified cases per 100,000 pop % of all TB/HIV cases world-wide are in Africa 50% of all TB/HIV cases world-wide in 9 African countries 23% of the estimated 2 million HIV deaths due to TB

Time trends in MDR-TB Available data from 74 countries and territories with measurements for at least two years could not answer the question of whether the proportion of previously untreated TB cases with MDR was increasing, decreasing or stable over time at a global or regional level.

Proportion of MDR among new TB cases Latest available data, The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.  WHO All rights reserved

Proportion of MDR among previously treated TB cases Latest available data, The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.  WHO All rights reserved

Countries that had reported at least one XDR-TB case by Oct 2011

Treatment Evolution for “Drug Sensitive” TB st regimen: Streptomycin PAS Isoniazid (H) 1963 Rifampin (R) discovered 1974 BMRC Trials add R & Z Pyrazinamide (Z) discovered – but liver toxicity Rx lasts from months Standard Regimen by 1960s based on 1952 drugs 1970 BMRC Trials add R Rx shortened to 9 months Standard Therapy 2 months: R, H, Z, E + 4 months: R, H Rx shortened to 6 months Strepto- mycin 1 st used for TB 1998 Rifapentine approved 1961 Ethambutol (E) discovered 9

The Burden of Therapy for Multi-drug Resistant TB Example of a typical regimen for MDR-TB Intensive phase of 6-9 months – aim to directly observe 6 days/week: –Six drug combination, one given by injection Continuation phase of 18 months: –Four drugs A patient may need longer therapy if sputum is not clear of TB at month 4 Note: If the patient has HIV, he/she may need to take 3 additional anti-retroviral drugs 10

The Burden of Therapy for Multi-drug Resistant TB The price of four medicines in particular weigh heavily in the overall cost of a DR-TB regimen. Overall costs of the DR-TB regimen are particularly driven by capreomycin, moxifloxacin, PAS, and cycloserine. For most DR-TB drugs, patents are not typically a factor in causing high prices, because the medicines were developed so long ago that patents on most have long run out. However, moxifloxacin is a notable exception—until now, Bayer’s monopoly has kept prices high. Some DR-TB drug prices have increased considerably between 2001 and 2011, including for the medicines procured through the GDF for GLC-approved treatment programs. This is true of the prices of amikacin (the most affordable source in 2011 costs eight times more the most affordable source in 2001), kanamycin (six times more), cycloserine, and capreomycin (both three times more). 11

MDR-TB Drug Prices

► Significant improvements in therapy are needed for all patient populations Patient Population Current Therapy Unmet Needs Drug-Susceptible TB 4 drugs; ≥6 month therapyShorter, simpler therapy Drug-Resistant M(X)DR-TB Few drugs (including injectables); ≥18 months therapy; toxicities Totally oral, shorter, more efficacious, safer and lower cost therapy TB/HIV Co-Infection Drug-drug interactions with HIV medications Ability to co-administer TB regimens with ARVs Latent TB Infection 6-9 months of treatmentShorter, safer therapy Children 4 drugs; ≥6 month therapy Shorter, simpler therapy with pediatric-friendly dosing Current TB Therapy and Unmet Needs 13

The Global TB Development Pipeline From the Stop TB Partnership Working Group on New Drugs 14

Tuberculosis Diagnosis: Then and Now

The Future of TB Diagnostics

– Xpert MTB/RIF : Level of the Health system: Peripheral laboratory, at district and sub-district level (intended for use in secure facilities with a reliable source of electricity) For LICs and MICs FIND negotiated a 75% reduction relative to the market price: $16.86 per cartridge $17,000 - $17,500 per Instrument But Not the POC diagnostic that is needed. Xpert MTP/RIF

Point-of-care: easy to perform in peripheral health centres Detect active TB in adults regardless of HIV status Improved diagnosis of TB in children Result that allow decision on treatment initiation Patient can receive result on the same day The TB Test We Need

Distance from Patients Intermediate level Lab Reference level New SS+ case definition 2-specimen approaches POC test (detection) Peripheral level Abbreviations DST: Drug susceptibility test NAAT: Nucleic acid amplification test LTBI: Latent TB infection POC: Point of care MODS: Microscopic observation drug-susceptibility NRA: Nitrate reductase assay CRI: Colorimetric redox indicator assay LED: Light-emitting diode LPA: Line probe assay Technologies or methods endorsed by WHO Rapid speciation Liquid culture & DST LPA for MDR-TB Non-commercial culture & DST (MODS, NRA,CRI) LPA for XDR-TB 10-40% 70% 95% % Access after 5 years Predictive LTBI Xpert MTB/RIF Rapid colorimetric DST Manual NAAT 1 st generation Manual NAAT 2 nd generation Technologies at late stages of development Technologies at early stages of development LED microscopy Same-day diagnosis

Tonight! From 7-8PM Meet in Hotel Lobby (with guest Salmaan Keshavjee, Harvard Medical School/Partners in Health) Let’s Start a Campaign to Drop the Price of MDR-TB Drugs!